Addex Therapeutics Ltd (NAS:ADXN)
$ 8.36 -0.35 (-4.02%) Market Cap: 8.95 Mil Enterprise Value: 5.44 Mil PE Ratio: 0 PB Ratio: 0.66 GF Score: 55/100

Full Year 2023 Addex Therapeutics Ltd Earnings Call Transcript

Apr 18, 2024 / 02:00PM GMT
Release Date Price: $20.96 (-4.73%)
Tim Dyer
Addex Therapeutics Ltd - Chief Executive Officer, Co-Founder, Member of the Executive Management, Director

Hello, everyone. I'd like to thank you all for attending our 2023 financial results conference call. I'm here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D programs. Throw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimer, we will be making certain forward-looking statements that are based on the knowledge we have today.

I will start this conference call by giving a quick overview of the 2023 activities and recent achievements. Before reviewing our pipeline, I will then hand over to Mikhail, who will review our more detail some of the clinical and preclinical programs. I will then speak about the recent launch of Neurosterix. Before reviewing our 2023 full year financial results. Following that, we will open the call for Q&A.

To start with the highlights. Our partner Janssen has completed the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot